Personalis (NASDAQ:PSNL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Personalis (NASDAQ:PSNL) from a sell rating to a hold rating in a report released on Saturday morning.

PSNL has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $8.50 price target on shares of Personalis in a research report on Monday, September 8th. BTIG Research set a $6.00 price target on shares of Personalis in a research report on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $7.42.

Personalis Stock Up 1.0%

PSNL stock opened at $6.16 on Friday. The company has a market capitalization of $546.27 million, a P/E ratio of -4.81 and a beta of 1.76. The company has a 50-day simple moving average of $5.40 and a 200 day simple moving average of $4.94. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $7.79.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. The business had revenue of $17.20 million during the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Several institutional investors and hedge funds have recently bought and sold shares of PSNL. Ameriprise Financial Inc. raised its holdings in Personalis by 38.3% during the 4th quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company’s stock worth $199,000 after buying an additional 9,535 shares during the period. BNP Paribas Financial Markets raised its holdings in Personalis by 53,126.7% during the 4th quarter. BNP Paribas Financial Markets now owns 71,856 shares of the company’s stock worth $415,000 after buying an additional 71,721 shares during the period. Two Sigma Investments LP raised its holdings in Personalis by 86.1% during the 4th quarter. Two Sigma Investments LP now owns 145,662 shares of the company’s stock worth $842,000 after buying an additional 67,403 shares during the period. Two Sigma Advisers LP grew its stake in Personalis by 25.6% during the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company’s stock valued at $198,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Squarepoint Ops LLC grew its stake in Personalis by 438.7% during the 4th quarter. Squarepoint Ops LLC now owns 91,684 shares of the company’s stock valued at $530,000 after acquiring an additional 74,664 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.